Deutsche Bank AG Has $331,000 Stock Holdings in Surmodics, Inc. $SRDX

Deutsche Bank AG reduced its position in shares of Surmodics, Inc. (NASDAQ:SRDX) by 74.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,850 shares of the company’s stock after selling 31,833 shares during the period. Deutsche Bank AG owned approximately 0.08% of Surmodics worth $331,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Millennium Management LLC increased its stake in shares of Surmodics by 0.4% in the 4th quarter. Millennium Management LLC now owns 120,344 shares of the company’s stock valued at $4,766,000 after purchasing an additional 509 shares during the last quarter. Principal Financial Group Inc. lifted its position in shares of Surmodics by 1.8% during the 1st quarter. Principal Financial Group Inc. now owns 36,699 shares of the company’s stock worth $1,120,000 after buying an additional 638 shares during the last quarter. Legal & General Group Plc boosted its stake in Surmodics by 34.2% in the fourth quarter. Legal & General Group Plc now owns 3,452 shares of the company’s stock valued at $137,000 after buying an additional 880 shares in the last quarter. Salem Investment Counselors Inc. boosted its stake in Surmodics by 1.1% in the first quarter. Salem Investment Counselors Inc. now owns 114,950 shares of the company’s stock valued at $3,509,000 after buying an additional 1,200 shares in the last quarter. Finally, Wells Fargo & Company MN grew its position in Surmodics by 40.9% in the fourth quarter. Wells Fargo & Company MN now owns 7,032 shares of the company’s stock valued at $278,000 after acquiring an additional 2,041 shares during the last quarter. 96.63% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have recently commented on SRDX shares. Barrington Research reissued a “market perform” rating on shares of Surmodics in a report on Monday, August 11th. Zacks Research upgraded shares of Surmodics to a “hold” rating in a research report on Tuesday, August 12th. One investment analyst has rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, Surmodics has an average rating of “Hold” and an average price target of $43.00.

Surmodics Stock Performance

NASDAQ:SRDX opened at $34.33 on Friday. The stock’s 50-day moving average is $33.29 and its 200-day moving average is $30.98. Surmodics, Inc. has a 1-year low of $26.00 and a 1-year high of $40.38. The company has a current ratio of 3.91, a quick ratio of 3.10 and a debt-to-equity ratio of 0.27. The stock has a market cap of $490.92 million, a P/E ratio of -27.91 and a beta of 1.31.

Surmodics (NASDAQ:SRDX) last issued its quarterly earnings data on Friday, August 8th. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.27. Surmodics had a negative net margin of 14.59% and a negative return on equity of 2.99%. The business had revenue of $29.57 million during the quarter, compared to analyst estimates of $28.04 million. Surmodics has set its FY 2025 guidance at -0.350–0.200 EPS. Equities research analysts anticipate that Surmodics, Inc. will post 0.2 earnings per share for the current year.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).